Market
Overview
The global hemophilia market is
forecasted to witness a steady growth of 6.10% during the forecast period
between 2018 to 2023. The market valuation is slated to jump from USD 11,257.21
in 2018 to USD 16,059.18 by the end of the forecast period.
The
report published by Market Research Future (MRFR) identifies that the
prevalence of hemophilia will spring up the demand for hemophilia treatment market
globally. The emergence of recombinant products for the treatment of hemophilia
has blossomed the interest and demand for the market. The absence of a precise
cure and the growing setbacks with the treatment of hemophilia has increased
the need for discovering and coming up with new and effective solutions. Gene
therapy is increasingly being explored and considered as a permanent solution
for hemophilia and offers vast opportunities for the growth of the market.
However,
the high cost associated with the treatment and the level of expenses required
for consistent lab testing and imaging tests can go on to hamper the market
growth of hemophilia treatment.
Market
Segmentation
The
global hemophilia treatment market segmentation is based in terms of type,
end-user, and treatment.
By
type, the market is categorized into hemophilia A, hemophilia B, and hemophilia
C. The hemophilia A segment holds the largest share of the global market. The
valuation of the segment is expected to reach USD 12.697.99 by the end of the
forecast period, 2023. The calculated growth rate of the market annually has
been projected to be 6.23% during the forecast period.
By
treatment, the market comprises of recombinant coagulation factor concentrates,
plasma-derived coagulation factor concentrates, desmopressin, gene therapy, and
antifibrinolytic agents. The recombinant coagulation factor concentrates is the
largest market share holder with an expected CAGR of 7.01% during the review
period.
By
end-users, the market includes hospitals & clinics, research organization,
and others. Hospitals & clinics lead this segmentation of the market and is
valued at USD 7594.66 in 2018 and is expected to grow the fastest over the
forthcoming years.
Regional
Analysis
The regional
segmentation of the hemophilia treatment market covers the following regions:
North America, Europe, Asia Pacific, Latin America, and the Middle East and
Africa.
The
Americas stand tall as the largest market share holder in the global
geographical segmentation. This is due to the prevalence of the hemophilia
disorder and the presence of a well-established healthcare sector. Growing
expenditure in healthcare and increasing support for research and development
activities are expected to aid the Americas region to maintain its leadership
position. The North American market contributes more to the region than its
southern counterpart.
Europe
holds the second biggest market share due to a parallel growth pattern like the
Americas. Moreover, government support for R&D activities for advanced
medical therapies for hemophilia is another important driver to the market
growth in this region.
Asia
Pacific is expected to grow with the highest CAGR of 8.38% during the review
period. The healthcare sector in this region is advancing at a rapid pace owing
to the high disposable income in the region and expanding advanced medical
facilities. The presence of a vast patient population base and a high
healthcare expenditure is expected to positively impact the Asia Pacific market
growth.
Competitive
Landscape
The
global hemophilia treatment market includes various noteworthy players like
Baxter, F.Hoffmann-La Roche Ltd, Octapharma, Swedish Orphan Biovitrum AB,
Pfizer Inc, CSL Behring, Sanofi, Kedrion, Novo Nordisk A/S, Bayer AG, Grifols
International S.A, and Shire.
Feb 19th, 2019, Novo Nordisk announced in a
press release about the US FDA approval of N8-GP, turoctocog alfa pegol, to
help treat children and adults with hemophilia A in the United States. The
therapy will be under the brand name of Esperoct
Feb 7th, 2019,
Roche announced its joining with the World Federation of Hemophilia (WFH)
Humanitarian Aid Program. The program will see the company treating more than
1,500 people with Hemophilia A across various developing countries.
About Market Research
Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum
quality market research and intelligence services to our clients. Our market
research studies by Components, Application, Logistics and market players for
global, regional, and country level market segments, enable our clients to see
more, know more, and do more, which help to answer all their most important
questions.
In order to stay updated with technology and work process of
the industry, MRFR often plans & conducts meet with the industry experts
and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
